Gastrointestinal tumours, non-colorectal
Gastrointestinal tumours, non-colorectal: Invited Discussant 620PD, 621PD, 622PD and 623PD
Date
11 Sep 2017Session
Gastrointestinal tumours, non-colorectalPresenters
Stefano CascinuAuthors
S. CascinuAuthor affiliations
- Department Of Oncology , AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, 60126 - Ancona/IT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
2143 - YOSEMITE: A 3 Arm Double-Blind Randomized Phase 2 Study of Gemcitabine, Paclitaxel Protein-Bound Particles for Injectable Suspension (Abraxane®) and Placebo (GAP) versus Gemcitabine, Abraxane® and either 1 or 2 Truncated Courses of Demcizumab (GAD).
Presenter: Antonio Cubillo Gracian
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
2743 - A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)
Presenter: Pascal Hammel
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3096 - nab-Paclitaxel (nab-P) Plus Gemcitabine (G) for Patients (Pts) With Locally Advanced Pancreatic Cancer (LAPC): Interim Efficacy and Safety Results From the Phase 2 LAPACT Trial
Presenter: Philip Philip
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1091 - A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC).
Presenter: Manuel Hidalgo
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
5988 - New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer
Presenter: Angela Alistar
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5986 - Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients
Presenter: Ewa Carrier
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
2205 - A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
2539 - Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial
Presenter: Michael Teufel
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
937 - A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)
Presenter: Takaki Yoshikawa
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3861 - Comparison of the eighth and seventh editions of the American Joint Committee on Cancer TNM staging systems for gastric cancer: proposal for a simplified and improved TNM staging system
Presenter: Junpeng Lin
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.